08:00 , Mar 8, 2010 |  BC Week In Review  |  Company News

ApaTech, Baxter deal

Baxter will acquire ApaTech for $240 million in cash, plus up to $90 million in sales milestones. Baxter said the deal will allow it to immediately enter the bone fusion business with ApaTech's Actifuse ,...
01:58 , Mar 2, 2010 |  BC Extra  |  Company News

Baxter to acquire ApaTech

Baxter International Inc. (NYSE:BAX) will acquire ApaTech Ltd. (Elstree, U.K.) for $240 million in cash plus up to $90 million in sales milestones. Baxter said the acquisition will allow it to immediately enter the bone...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

Actifuse musculoskeletal data

A prospective evaluation of 2-year data from 38 patients with lumbar stenosis undergoing posterolateral lumbar fusion with Actifuse showed that fusion rates were >81% at 2 years, with 90% of patients achieving a fusion in...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

Actifuse musculoskeletal data

A retrospective analysis of data collected from 69 patients with degenerative lumbar spine disease undergoing decompressive surgery with posterolateral spinal fusion with Actifuse showed that 81% had radiographic evidence of bilateral bridging bone 1 year...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Company News

ApaTech, Ceremed sales and marketing update

ApaTech launched Actifuse Shape in Europe for use in bone graft procedures to accelerate bone formation and improve the organization and strength of the graft/host bone composite structure. The biostimulative scaffold, which combines ApaTech's microgranules...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

Actifuse regulatory update

FDA granted 510(k) clearance for ApaTech's Actifuse for use in orthopedic applications as a filler for gaps and voids that are not intrinsic to the stability of the bony structure. Actifuse is a calcium phosphate...